Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 29102 in atopic dermatitis
NCT01037881Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Dec 2009
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of lotamilast in atopic dermatitis (AD) (7 arms), sponsored by LEO Pharma. Primary endpoint: Absolute Change in Eczema Area and Severity Index Score From Baseline at Day 28. Started Dec 2009; status: completed.
02
Drugs
lotamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01037881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037881.